Angioplasty versus stenting for superficial femoral artery lesions (protocol stage)

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair (protocol stage)

Antiplatelet agents for intermittent claudication (protocol stage)

Atherectomy for peripheral arterial disease (protocol stage)

Autologous versus prosthetic arteriovenous fistulae for vascular access (protocol stage)

Beta blockers for peripheral arterial disease (protocol stage)

Beta-adrenergic blockers for perioperative cardiac risk reduction in patients undergoing vascular surgery (protocol stage)

Calcium channel blockers for primary Raynaud's Phenomenon (protocol stage)

Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high risk patients (protocol stage)

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement (protocol stage)

Endoluminal stents for superficial femoral and popliteal artery occlusions in patients with lower limb peripheral artery disease (protocol stage)

Endovascular repair of abdominal aortic aneurysm (protocol stage)

Endovascular versus conventional treatment for type B aortic dissection (protocol stage)

Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus conventional surgery for long saphenous vein varices. (protocol stage)

Fibrinolytic agents for peripheral arterial occlusion (protocol stage)

Gene therapy for peripheral arterial disease (protocol stage)

Ginkgo biloba for intermittent claudication (protocol stage)

Graft materials for open abdominal aortic aneurysm repair (protocol stage)

Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and MI) (protocol stage)

Intravenous immunoglobulin for Wegener's granulomatosis (protocol stage)

Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis (protocol stage)

L-carnitine for intermittent claudication (protocol stage)

Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children (protocol stage)

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower leg immobilization (protocol stage)

Pentasaccharides for the prevention of venous thromboembolism (protocol stage)

Pentoxifylline for intermittent claudication (protocol stage)

Physical treatments for non-complicated chronic venous insufficiency (protocol stage)

Physiotherapeutic mechanisms for prevention of deep vein thrombosis in patients at risk of haemorrhage (protocol stage)

Prevention of venous insufficiency in a standing workers population (protocol stage)

Prostanoids for critical limb ischemia (protocol stage)

Risk assessment versus no risk assessment for preventing deep vein thrombosis and pulmonary embolism in surgical patients (protocol stage)

Rutosides for prevention of post thrombotic syndrome (protocol stage)

Rutosides for treatment of post-thrombotic syndrome (protocol stage)

Steroid hormone treatment for Kawasaki disease in children (protocol stage)

Subcutaneous unfractionated heparin for the treatment of venous thromboembolism (protocol stage)

Sympathectomy for peripheral arterial disease (protocol stage)

Thoracic stent graft versus surgery for thoracic aneurysm (protocol stage)

Thoracic stent graft versus surgery for traumatic thoracic transection (protocol stage)

Thrombophilia testing for prevention of recurrent venous thromboembolism (protocol stage)